BioSpace News Archive

Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2022 financial results after market close on Wednesday, August 3, 2022.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended June 30, 2022 and provided an update on its product pipeline and corporate activities.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4, 2022, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the market.

Medpace Holdings, Inc. announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial Results Revenue for the three months ended June 30, 2022 increased 26.2% to $351.2 million, compared to $278.3 million for the comparable prior-year period.

Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $164.1 million, or $2.20 per diluted share, during the second quarter of 2022, as compared to $325.0 million, or $3.79 per diluted share, during the second quarter of 2021.

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results on Monday, August 1, 2022, before the U.S. financial markets open.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2022, after the close of market on Monday, Aug. 8, 2022.

Zoetis Inc. (NYSE: ZTS) today announced the appointment of Vanessa Broadhurst, Executive Vice President, Global Corporate Affairs at Johnson & Johnson, to its Board of Directors.

Humacyte, Inc. announced results evaluating the use of the small-diameter Human Acellular Vessel for coronary artery bypass grafting in a non-human primate model.